Target intelligence / Profile preview

SPECC1L-ADORA2A readthrough transcript (SPECC1L-ADORA2A)

Target
SPECC1L-ADORA2A
Molecular classification
Non-coding RNA, Readthrough transcript
01

Overview

The SPECC1L-ADORA2A readthrough is a naturally occurring non-coding RNA transcript generated by readthrough transcription between the adjacent SPECC1L and ADORA2A genes on chromosome 22. This chimeric transcript is a candidate for nonsense-mediated decay and is not believed to produce any functional protein. There are no known biological functions, disease roles, or pharmacological targets associated with the SPECC1L-ADORA2A transcript itself. It is not considered a therapeutic target or a receptor, enzyme, transporter, or other protein product[1][3].\n\n**Note**: The individual genes involved in the readthrough—**SPECC1L** (a cytoskeletal protein involved in cell adhesion and migration) and **ADORA2A** (a G protein–coupled adenosine receptor gene)—have biological significance. However, this specific readthrough does not encode a functional molecule and is not a therapeutic target[1][3].\n\n**Summary of error**: SPECC1L-ADORA2A is not a canonical protein target but instead a non-coding readthrough transcript, so should not be annotated as a therapeutic or functional biomolecular target[1][3].

Other names
SPECC1L-ADORA2A
02

Disease associations

Teebi Hypertelorism Syndrome 1 (for the individual genes, not the readthrough)Oblique Facial Cleft (for the individual genes, not the readthrough)[1]

Beyond the preview

Go deeper on SPECC1L-ADORA2A readthrough transcript (SPECC1L-ADORA2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPECC1L-ADORA2A readthrough transcript (SPECC1L-ADORA2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call